Souhaitez-vous accéder aux communiqués récents ?

2020 Half-year results: Stronger financial position and research programs moving forward despite the international context Clinical program for the antibiotic candidate DNV3837 continues, with the...

DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak  DEINOVE (Euronext Growth Paris: ALDEI), a French biotech...

Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences field, particularly in microbiology applied to health and...

Luminity® is a concentrate of neurosporene, an extremely rare carotenoid that contributes to skin vitality and a beautiful complexion. Clinical tests have confirmed its ability to boost...

BIOME Oléoactif® is an exclusive active ingredient that regulates skin microbiota and reinforces skin barrier function, thanks to a unique composition of innovative active molecules.This...

DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance The AGIR program, supported by the French Investments for the Future program, aims to accelerate new...

DEINOVE étoffe sa gamme commerciale d’ingrédients cosmétiques Son deuxième caroténoïde innovant présente notamment la particularité d’absorber la lumière bleue, responsable du vieillissement...

DEINOVE expands its range of cosmetic active ingredients Its second innovative carotenoid has the particularity of absorbing blue light, which is responsible for premature skin ageing, the appearance...

Sharon Laboratories capitalizes on Deinove to sustain its development activities The signed Memorandum of Understanding (MoU) covers the development and marketing of an exclusive range of bio-based...

Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837...